| Patient | Evel Knievel |
|---|---|
| Date of birth | 1938-10-17 |
| Identifiers | MRN HR-RB001-SYN-TD; SSN (made up) 000-01-4927 |
| Document date | 1996-05-18 |
| Author | Dale Rasmussen, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
End of 12 weeks of hepatitis C treatment. [S]
Mr. Knievel finished sofosbuvir-velpatasvir yesterday without missing a dose. He has had no alcohol since the day treatment started. He takes carvedilol 12.5 mg daily without dizziness. His glucose sensor has shown no readings below 70 mg/dL. The bone density scan ten weeks ago showed osteoporosis at the hip. He has had no falls since starting physical therapy, walks 20 minutes on flat ground and swims twice a week; pain is about 4 of 10. He has not yet had his diabetic eye examination because the appointment was not booked after the referral. He saw his dentist last week. He has had no muscle aches, abdominal swelling, black stools, confusion or yellow eyes. He has had no thoughts of self-harm. [S]
| Element | Detail |
|---|---|
| Treatment | 12 weeks of sofosbuvir-velpatasvir completed; no missed doses |
| Alcohol | None for 12 weeks |
| Bone density | Femoral neck T-score -2.6; lumbar spine -1.9 |
| Glucose sensor | Glucose management indicator 6.9%; no lows |
| Eye examination | Not yet done |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | More energy; weight down 1.6 kg |
| Gastrointestinal | Negative | No abdominal swelling, black stools or nausea |
| Musculoskeletal | Positive | Hip and knee pain, 4 of 10; no muscle aches |
| Endocrine | Negative | No low glucose readings |
| Neurological | Negative | No confusion or tremor |
| Psychiatric | Negative | Mood good; PHQ-9 4; no thoughts of self-harm |
6 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Metformin 1000 mg oral tablet, one tablet by mouth twice daily with meals | One tablet twice daily with breakfast and supper | Oral route | 1991-03-01 | active | S |
| Ibuprofen 800 mg oral tablet, one tablet three times a day for joint and back pain | One tablet three times a day | Oral route | 1994-06-01 to 1996-01-12 | completed | S |
| Omeprazole 20 mg delayed-release oral capsule, one capsule daily for indigestion from ibuprofen | One capsule daily before breakfast | Oral route | 1994-06-01 to 1996-01-12 | completed | S |
| Acetaminophen 500 mg oral tablet, two tablets by mouth up to twice a day as needed for pain, no more than 2 g a day | Two tablets up to twice a day as needed; no more than 2 g a day | Oral route | 1996-01-12 | active | S |
| Diclofenac sodium 1% topical gel, 4 g to the knees up to four times a day | 4 g to each knee up to four times a day | Topical route | 1996-01-12 | active | S |
| Carvedilol 6.25 mg oral tablet, one tablet daily | One tablet daily | Oral route | 1996-01-26 to 1996-02-23 | completed | S |
| Carvedilol 12.5 mg oral tablet, one tablet daily | One tablet daily | Oral route | 1996-02-23 | active | S |
| Atorvastatin 20 mg oral tablet, one tablet daily | One tablet daily | Oral route | 1996-01-26 | active | S |
| Sofosbuvir 400 mg and velpatasvir 100 mg oral tablet, one tablet daily for 12 weeks | One tablet daily for 12 weeks | Oral route | 1996-02-23 to 1996-05-17 | completed | S |
| Cholecalciferol (vitamin D3) 50 mcg (1970 units) oral capsule, one capsule daily | One capsule daily | Oral route | 1996-02-23 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1996-05-18 | Body height | 178 | cm | S |
| 1996-05-18 | Body weight | 83.2 | kg | S |
| 1996-05-18 | Body mass index (BMI) [Ratio] | 26.3 | kg/m2 | S |
| 1996-05-18 | Systolic blood pressure | 118 | mm[Hg] | S |
| 1996-05-18 | Diastolic blood pressure | 72 | mm[Hg] | S |
| 1996-05-18 | Heart rate | 62 | /min | S |
| 1996-05-18 | Respiratory rate | 14 | /min | S |
| 1996-05-18 | Body temperature | 36.5 | Cel | S |
| 1996-05-18 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1996-05-18 | Hemoglobin [Mass/volume] in Blood | 14.2 | g/dL | 13.5-17.5 g/dL | Normal | S |
| 1996-05-18 | Leukocytes [#/volume] in Blood by Automated count | 5 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 1996-05-18 | Platelets [#/volume] in Blood by Automated count | 129 | 10*3/uL | 150-400 10*3/uL | Low | S |
| 1996-05-18 | Creatinine [Mass/volume] in Serum or Plasma | 0.89 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 1996-05-18 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1991)/1.73 sq M | 100 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 1996-05-18 | Glucose [Mass/volume] in Serum or Plasma | 118 | mg/dL | 70-99 mg/dL | High | S |
| 1996-05-18 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 24 | U/L | 7-55 U/L | Normal | S |
| 1996-05-18 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 29 | U/L | 8-48 U/L | Normal | S |
| 1996-05-18 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.8 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 1996-05-18 | Albumin [Mass/volume] in Serum or Plasma | 3.9 | g/dL | 3.5-5 g/dL | Normal | S |
| 1996-05-18 | Calcium [Mass/volume] in Serum or Plasma | 9.3 | mg/dL | 8.6-10.3 mg/dL | Normal | S |
| 1996-05-18 | Hepatitis C virus RNA [Units/volume] (viral load) in Serum or Plasma by NAA with probe detection | 0 | [IU]/mL | Not detected is reported as 0; lower limit of quantification 15 IU/mL | Normal | S |
| 1996-05-18 | Hemoglobin A1c/Hemoglobin.total in Blood | 6.4 | % | Below 5.7% is normal; individual goal below 7%; may read falsely low in cirrhosis | High | S |
| 1996-05-18 | Glucose management indicator | 6.9 | % | Individual goal below 7% | Normal | S |
| 1996-05-18 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 34 | ng/mL | 30-100 ng/mL | Normal | S |
| 1996-05-18 | Parathyrin.intact [Mass/volume] in Serum or Plasma | 48 | pg/mL | 15-65 pg/mL | Normal | S |
| 1996-05-18 | Testosterone [Mass/volume] in Serum or Plasma | 455 | ng/dL | 264-916 ng/dL | Normal | S |
| 1996-05-18 | Total score [AUDIT-C] | 0 | {score} | S | ||
| 1996-05-18 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 4 | {score} | S | ||
| 1996-05-18 | Pain severity - 0-10 verbal numeric rating [Score] - Reported | 4 | {score} | S |
Vital signs recorded on 1996-05-18; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; weight 83.2 kg; blood pressure 118/72, pulse 62 |
| Skin | Spider angiomas fewer; no jaundice |
| Abdomen | Spleen tip palpable; no ascites |
| Mouth | Teeth in good repair |
| Neurological | No asterixis; gait steady with a cane |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Raised transaminases (ALT 88, AST 96 U/L) and low platelets (118) on today's tests, with spider angiomas and palmar erythema, in a man of 57 who received many blood transfusions after crashes before 1962 and drinks most evenings: chronic liver disease, most likely hepatitis C, must be excluded. Hepatitis C antibody with reflex RNA, hepatitis A and B serology, HIV, liver ultrasound and hepatology review ordered | resolved | confirmed | R74.01 | S — Synthetic presenting problem; no symptom or result of his real illness was made public. Superseded at the hepatology consultation. |
| Chronic hepatitis C, genotype 1a, treatment-naive, HCV RNA 2.35 million IU/mL, likely acquired through blood transfusions after crashes; synthetic modern detail linked to his publicly reported transfusion-acquired hepatitis C | active | confirmed | B18.2 | S — Synthetic genotype, viral load and timing; his hepatitis C and its likely transfusion source are documented (D). |
| Compensated cirrhosis from hepatitis C, with alcohol as a cofactor: liver stiffness 26.8 kPa, FIB-4 4.94, nodular liver and a 14.2 cm spleen on ultrasound, platelets 118; Child-Pugh A5, MELD-Na 8; no ascites, encephalopathy, jaundice or bleeding | active | confirmed | K74.69 | S — Synthetic stage of liver disease linked to his documented hepatitis C and later liver transplant. |
| Clinically significant portal hypertension in compensated cirrhosis (liver stiffness 25 kPa or more), treated with carvedilol without screening endoscopy (Baveno VII) | active | confirmed | K76.6 | S — Synthetic finding at the hepatology consultation. |
| Type 2 diabetes on metformin, A1c 7.4% | active | confirmed | E11.65 | S — Synthetic; diabetes is documented only in his last years (D), and placing it at 57 is a synthetic choice. |
| Chronic pain in the back, hips, pelvis and knees after dozens of fractures from stunt crashes, including a broken pelvis; ibuprofen stopped, and managed without oral NSAIDs or opioids | active | confirmed | G89.29 | S — Synthetic pain at the index age, anchored to his documented fractures and the pain of his later years. |
| Osteoporosis in a man with cirrhosis, prior heavy alcohol use and dozens of old fractures: femoral neck T-score -2.6, lumbar spine -1.9 | active | confirmed | M81.8 | S — Synthetic bone density result. |
| Vitamin D deficiency (25-hydroxyvitamin D 17 ng/mL) | resolved | confirmed | E55.9 | S — Synthetic finding before the bone density scan. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | HCV RNA at the end of treatment | Optional at the end of treatment | Completed today | Not detected |
| Laboratory | Hepatic function panel, blood count and kidney function | At the end of treatment in cirrhosis, as needed | Completed today | ALT 24, AST 29 U/L, bilirubin 0.8 mg/dL, albumin 3.9 g/dL; platelets 129, hemoglobin 14.2 g/dL, white cells 5.0; creatinine 0.89 mg/dL, eGFR 100 |
| Medication safety | Adherence and side effects | During treatment | Completed today | No missed doses; no side effects; no muscle aches on atorvastatin |
| Laboratory | Glucose control in cirrhosis: A1c with sensor data | Every three months when therapy changes | Completed today | A1c 6.4%; glucose management indicator 6.9%; fasting glucose 118 mg/dL; no hypoglycemia |
| Referral | Diabetic eye examination | Yearly | Deferred | A deviation: referred two visits ago but never booked, because the referral was sent without an appointment request. No harm is known; he has no visual symptoms. Corrective action: booked today for next month, with a reminder to confirm the result |
| Imaging | Bone density (DXA) | Men at risk | Up to date | Ten weeks ago: femoral neck T-score -2.6, lumbar spine -1.9; FRAX hip fracture risk 4.1% |
| Laboratory | Secondary causes of osteoporosis and calcium before zoledronic acid | Before starting treatment | Completed today | Vitamin D 34 ng/mL, calcium 9.3 mg/dL, parathyroid hormone 48 pg/mL, testosterone 455 ng/dL |
| Medication safety | Dental review before a bisphosphonate | Before the first dose | Up to date | Seen by his dentist last week |
| Medication safety | Carvedilol: blood pressure and heart rate | Each visit | Completed today | 118/72, pulse 62 |
| Imaging | Liver ultrasound for cancer surveillance | Every six months in cirrhosis | Due | Due in July, six months after the baseline scan |
| Examination | Signs of decompensation (ascites, encephalopathy, jaundice, bleeding) | Each visit in cirrhosis | Completed today | None |
| Self-management | Falls and fracture risk | Each visit | Completed today | No falls since physical therapy; cane outdoors |
| Survey | Alcohol use (AUDIT-C) | Each visit in liver disease | Completed today | AUDIT-C 0 |
| Survey | Pain score and function | Each visit | Completed today | 4 of 10 |
| Survey | Depression screen (PHQ-9) | At diagnosis and when treatment changes | Completed today | PHQ-9 4 |
Goal progress:
Guideline basis: AASLD-IDSA HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. Simplified HCV treatment algorithm for treatment-naive adults with compensated cirrhosis (2023); AASLD-IDSA HCV Guidance: Monitoring patients who are starting HCV treatment, are on treatment, or have completed therapy (2026); EPCLUSA (sofosbuvir and velpatasvir) tablets, prescribing information (2025); Singal AG, et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology 2023;78(6):1922-1965 (PMID 37199193) (2023); de Franchis R, et al. Baveno VII - Renewing consensus in portal hypertension. J Hepatol 2022;76(4):959-974 (PMID 35120736) (2022); Kaplan DE, et al. AASLD Practice Guidance on risk stratification and management of portal hypertension and varices in cirrhosis. Hepatology 2024;79(5):1180-1211 (PMID 37870298) (2024); Biggins SW, et al. Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the AASLD. Hepatology 2021;74(2):1014-1048 (PMID 33942342) (2021); Crabb DW, et al. Diagnosis and Treatment of Alcohol-Associated Liver Diseases: 2019 Practice Guidance From the AASLD. Hepatology 2020;71(1):306-333 (PMID 31314133) (2019); Rakoski M, Goyal P, Spencer-Safier M, et al. Pain management in patients with cirrhosis. Clin Liver Dis (Hoboken) 2018;11(6):135-140 (PMID 30992804) (2018); Dowell D, et al. CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022. MMWR Recomm Rep 2022;71(3):1-95 (PMID 36327391) (2022); American Diabetes Association. 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes-2026. Diabetes Care 2026;49(Suppl 1):S61-S88 (PMID 41358897) (2026); American Diabetes Association. 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026. Diabetes Care 2026;49(Suppl 1):S132-S149 (PMID 41358894) (2026); Watts NB, et al. Osteoporosis in men: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2012;97(6):1802-1822 (PMID 22675062) (2012); Unhealthy Alcohol Use in Adolescents and Adults: Screening and Behavioral Counseling Interventions (2018); CMID: Clinical Monitoring Intelligence Database, diabetes type 2, osteoporosis and depression monographs (2026); Depression and Suicide Risk in Adults: Screening (2023)
Follow-up: Zoledronic acid infusion in two weeks. Eye examination next month. Liver ultrasound in July. Review with HCV RNA, liver tests and alpha-fetoprotein 12 or more weeks after the last dose. Next scheduled visit 1996-08-17: cure confirmed (SVR12): six-month liver cancer surveillance, cirrhosis care after cure, and transplant criteria reviewed. [S]